Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $235,152.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 27,600 shares of Xeris Biopharma stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total value of $235,152.00. Following the transaction, the insider directly owned 1,366,053 shares in the company, valued at approximately $11,638,771.56. This trade represents a 1.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Trading Down 0.6%

Xeris Biopharma stock opened at $8.62 on Friday. The stock has a market cap of $1.49 billion, a P/E ratio of 143.67 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.87 and a 12 month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company’s fifty day simple moving average is $6.81 and its 200-day simple moving average is $6.67.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. As a group, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in XERS. Bank of America Corp DE boosted its position in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock valued at $5,072,000 after buying an additional 156,483 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after acquiring an additional 225,602 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Xeris Biopharma by 19.3% in the 1st quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after purchasing an additional 29,168 shares during the last quarter. Royal Bank of Canada boosted its holdings in Xeris Biopharma by 12.9% during the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after buying an additional 4,974 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Xeris Biopharma by 59.0% during the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock valued at $422,000 after purchasing an additional 27,003 shares during the period. 42.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.